Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published-Ahead-of-Print February 22, 2008, DOI:10.2164/jandrol.107.004218
Journal of Andrology, Vol. 29, No. 4, July/August 2008
Copyright © American Society of Andrology
DOI: 10.2164/jandrol.107.004218

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/4/408    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Marcon, L.
Right arrow Articles by Robaire, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcon, L.
Right arrow Articles by Robaire, B.

Reversibility of the Effects of Subchronic Exposure to the Cancer Chemotherapeutics Bleomycin, Etoposide, and Cisplatin on Spermatogenesis, Fertility, and Progeny Outcome in the Male Rat

LUDOVIC MARCON*, BARBARA F. HALES* AND BERNARD ROBAIRE*,{dagger}

From the Departments of * Pharmacology and Therapeutics and {dagger} Obstetrics and Gynecology, McGill University, Montreal, Canada

Correspondence to: Dr Bernard Robaire, Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir William Osler, Montreal, Quebec, Canada, H3G 1Y6 (e-mail: Bernard.robaire{at}mcgill.ca).


Testicular cancer is the most common cancer among young men of reproductive age. A regimen of bleomycin, etoposide, and cisplatin (BEP regimen) is the standard chemotherapy for testicular cancer. BEP has adverse effects on spermatogenic function that pose a long-term reproductive health risk to cancer survivors and their progeny. Using a rat model, we investigated the persistence of the effects of BEP on male reproductive function, fertility, and progeny outcome. Adult male Sprague-Dawley rats received a BEP regimen mimicking human clinical exposure (three 21-day cycles of etoposide and cisplatin on days 1–5 and bleomycin on days 2, 9, and 16, or vehicle). Reproductive and progeny outcome parameters were assessed at the end of BEP treatment and up to 9 weeks post-treatment, at 3-week intervals. BEP treatment reduced testicular weights and impaired spermatogenesis, characterized by abnormal testis histology and germ cell depletion. Germ cell apoptosis increased at least 3-fold in BEP-treated rats compared with controls at the end of treatment; 9 weeks posttreatment, germ cell apoptosis in BEP-treated rats did not differ from controls. BEP-exposed males were fertile; a decrease in litter size and an increase in preimplantation and postimplantation losses were observed. Preimplantation loss remained elevated in litters sired by BEP-treated males up to 9 weeks posttreatment; however, neither postimplantation loss nor litter sizes differed from controls. Thus, both germ cell apoptosis and the postimplantation loss induced by BEP treatment were reversible. The persistence of the elevation in preimplantation loss 9 weeks after BEP treatment suggests that spermatogonia are affected.

     Key words: Cancer therapeutics, testis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by The American Society of Andrology.